Developer docs
API playgroundTry for free, no card

Search company profiles

Sentynl Therapeutics, Inc.

Full company profile

uuid0006e97

Namestring
Sentynl Therapeutics, Inc.
Legal namestring
Sentynl Therapeutics, Inc.
Websiteurl
sentynl.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Sentynl Therapeutics, Inc. is a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited (India), founded in 2015 and headquartered in Solana Beach, California. The company specializes in acquiring, developing, and commercializing treatments for rare and ultra-rare pediatric genetic diseases through a buy-and-commercialize model, with a current commercial portfolio of three FDA-approved therapies: ZYCUBO (copper histidinate) for Menkes disease, Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome, and NULIBRY (fosdenopterin) for molybdenum cofactor deficiency Type A. Its technology foundation rests on proprietary drug formulations including subcutaneous copper replacement, farnesyltransferase inhibition, and cPMP substrate therapy, each targeting fatal genetic conditions that previously had no approved treatment options.

The business model centers on pharmaceutical product sales through specialty pharmacy distribution channels in the United States, supplemented by outbound royalty obligations on licensed products (e.g., tiered royalties to Cyprium Therapeutics on ZYCUBO net sales plus up to $128-129 million in aggregate sales milestones). Sentynl monetizes its portfolio through a sales-led enterprise field model employing Rare Disease Key Account Managers, Medical Science Liaisons, and an inside Key Account Consultant team that engages healthcare professionals at treatment centers of excellence. The Sentynl Cares patient support program facilitates insurance navigation and affordability assistance, while a Managed Access Program (now operated by Amsterdam-based myTomorrows) extends reach for international patients. Revenue figures are not publicly disclosed, though analyst projections estimate ZYCUBO peak sales of approximately $50 million and company-wide profitability by FY28. With 11-50 employees, the firm operates a focused ultra-rare disease specialty model targeting indications with no approved competitors.

Short descriptiontext

Sentynl Therapeutics is a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences that acquires, develops, and commercializes FDA-approved therapies for rare and ultra-rare pediatric genetic diseases including Menkes, Progeria, and MoCD Type A.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSolana Beach, United States
HQ citystring
Solana Beach
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, orphan drug development, specialty pharmaceuticals, pediatric genetic diseases, ultra-rare disease treatments
Industry1 code
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Rare Disease Therapeutics
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue from sales of FDA-approved rare disease therapies including ZYCUBO for Menkes disease, Zokinvy for Progeria, and NULIBRY for MoCD Type A. Products distributed through specialty pharmacy channels with patient support programs.

prnewswire.com
2Royalty Revenue
TypeLicensing Royalties
Description

Sentynl pays royalties to Cyprium Therapeutics on ZYCUBO net sales (tiered royalties) plus up to $128-129 million in aggregate sales milestones, per 2023 agreement. Also likely pays royalties on other licensed products.

biospace.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Patient assistance program for US residents
ModelOtherBilling cadencePay-as-you-go
Notes

Sentynl Cares program offers access and support options based on individual needs, insurance coverage, and affordability. Call 1-888-251-2800 Monday-Friday, 8am-8pm ET.

sentynl.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Sentynl Cares
Description

Patient access and support program offering assistance with insurance coverage, affordability issues, and treatment education for patients prescribed Sentynl therapies.

sentynl.com
Core offering1 text field

Sentynl Therapeutics is a U.S.-based commercial-stage biopharmaceutical company that develops, in-licenses, and commercializes FDA-approved drug therapies for ultra-rare pediatric genetic diseases. Its marketed portfolio comprises ZYCUBO (copper histidinate) for Menkes disease, Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome, and NULIBRY (fosdenopterin) for molybdenum cofactor deficiency Type A, distributed through specialty pharmacy channels and supported by the Sentynl Cares patient access program.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 78-80% reduction in risk of death for early-treated Menkes disease patients (median survival 177.1 months vs 17.6 months untreated)
+2 more records
Product overview1 text field

Sentynl Therapeutics is a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences, focused on acquiring, developing, and commercializing treatments for rare and ultra-rare diseases. The company's commercial portfolio includes three FDA-approved products: ZYCUBO (copper histidinate) for Menkes disease, Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome, and NULIBRY (fosdenopterin) for molybdenum cofactor deficiency Type A. Additionally, Sentynl is advancing Progerinin through Phase 2A trials for Progeria. The company operates exclusively in the United States and supports patients through the Sentynl Cares patient access program.

Product and service5 records
1ZYCUBO (copper histidinate)
CategoryRare disease pharmaceutical (Menkes disease)
Description

FDA-approved copper replacement therapy for the treatment of Menkes disease in pediatric patients. Administered subcutaneously as a lyophilized powder reconstituted for injection, it is the first and only approved treatment for this rare, fatal genetic disorder affecting copper absorption and transport, demonstrating 78–80% reduction in mortality risk in early-treated patients.

2Zokinvy (lonafarnib)
CategoryRare disease pharmaceutical (Progeria)
Description

FDA-approved oral farnesyltransferase inhibitor treatment for Hutchinson-Gilford Progeria Syndrome and processing-deficient progeroid laminopathies. It is the only FDA-approved treatment for progeria, a fatal genetic disorder causing premature aging in children, with approvals in the US (2020), EU (2022), Great Britain (2022), and Japan (2024).

3NULIBRY (fosdenopterin)
CategoryRare disease pharmaceutical (MoCD Type A)
Description

Approved substrate replacement therapy for molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that progresses rapidly in infants with a median overall survival age of about four years. Approved in the US (2021), EU (2022), Israel (2022), and Great Britain (2024).

4Progerinin (SLC-D011)
CategoryInvestigational rare disease pharmaceutical (Progeria pipeline)
Description

Investigational drug candidate for Hutchinson-Gilford Progeria Syndrome currently in Phase 2A clinical trials. Licensed from PRG S&T, with Sentynl gaining full rights upon milestone completion, advancing the company's pipeline in rare aging diseases.

5Sentynl Cares
CategoryPatient support program
Description

Patient access and support program providing insurance navigation, affordability assistance, treatment follow-up, and educational resources for US residents prescribed Sentynl rare disease therapies, helping patients access approved treatments such as ZYCUBO, Zokinvy, and NULIBRY.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-16
Description

Sentynl entered agreement with Korean company PRG S&T to license Progerinin (SLC-D011), an investigational drug for Hutchinson-Gilford Progeria Syndrome currently in Phase 2A trials. Deal allows Sentynl to begin clinical development with full rights potentially acquired upon milestone completion, aiming to develop therapies for rare aging diseases.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-23
Description

Sentynl acquired CUTX-101 (ZYCUBO) development and commercialization rights from Cyprium in December 2023. Cyprium retains tiered royalties on net sales and up to $128-129 million in sales milestones. Sentynl purchased PRV for $205 million in February 2026. Joint Steering Committee oversees continued development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-10
Description

Sentynl transitioned its Managed Access Program (MAP) to myTomorrows, a global healthtech company based in Amsterdam. The partnership aims to expand the program's reach and improve access to treatments for ultra-rare conditions like Hutchinson-Gilford Progeria Syndrome, with potential extension to other access programs.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-05-03
Description

Sentynl acquired global proprietary rights to Zokinvy (lonafarnib) from Eiger BioPharmaceuticals in May 2024 following court-approved sale amid Eiger's bankruptcy proceedings. Zokinvy is approved in US (2020), EU, Great Britain (2022), and Japan (2024) for progeria treatment.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-07-20
Description

Sentynl is a founding member of BeginNGS program supporting newborn screening for 419 treatable genetic disorders. Phase 2 support to identify treatable genetic diseases in newborns through genomic sequencing.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-03-08
Description

Asset purchase agreement for NULIBRY (fosdenopterin) for treatment of MoCD Type A. NULIBRY is first and only approved therapy in US, EU, Israel, and Great Britain for this ultra-rare, life-threatening genetic disorder.

7Menkes Foundation
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Sentynl joins the global Menkes disease community including the Menkes Foundation in recognizing Menkes Disease Awareness Month. Collaboration on disease awareness and patient support.

sentynl.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Pharmaceutical group with dedicated rare disease division offering treatments for rare conditions globally. Comparable in rare disease commercialization but operates within broader specialty pharma portfolio.

TypeEmerging player
Description

Commercial-stage biopharmaceutical company developing RNA interference therapeutics for rare genetic diseases. Comparable focus on rare diseases with novel therapeutic modalities and similar ultra-rare disease commercial dynamics.

TypeEmerging player
Description

Biopharmaceutical company developing antisense oligonucleotide therapies for serious and rare diseases. Comparable in targeting rare genetic conditions with novel therapeutic platforms and similar patient population scale.

TypeBroad incumbent
Description

Pioneer in rare disease biopharmaceuticals, now part of AstraZeneca. Comparable ultra-rare disease focus with established global infrastructure but operates at significantly larger scale as part of a major pharma.

TypeDirect peer
Description

Biopharmaceutical company developing treatments for rare metabolic diseases including lysosomal storage disorders. Comparable focus on genetic rare diseases with high unmet need and similar commercial scale.

TypeDirect peer
Description

Genetic disease-focused biopharmaceutical company that developed NULIBRY before selling it to Sentynl. Direct comparable in ultra-rare genetic disease therapeutic development and commercialization strategy.

TypeDirect peer
Description

Focused on rare neuromuscular diseases with multiple approved genetic medicines. Comparable strategy of acquiring/developing orphan drugs for small patient populations with high pricing power.

TypeDirect peer
Description

Commercial-stage biopharmaceutical company focused exclusively on rare and ultra-rare genetic diseases with multiple FDA-approved products. Highly comparable business model of developing and commercializing therapies for small patient populations with high unmet need.

TypeDirect peer
Description

Global biopharmaceutical company specializing in rare genetic diseases with multiple approved therapies. Comparable focus on ultra-rare pediatric disorders and similar commercial model targeting specialty physicians and treatment centers.

TypeDirect peer
Description

Specialty biopharmaceutical company focused on rare diseases with established European and US operations. Comparable orphan drug commercialization model targeting ultra-rare patient populations across multiple geographies.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sentynl Therapeutics, Inc.

Rare Disease Therapeuticssentynl.com

Sentynl Therapeutics is a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences that acquires, develops, and commercializes FDA-approved therapies for rare and ultra-rare pediatric genetic diseases including Menkes, Progeria, and MoCD Type A.

What Sentynl Therapeutics, Inc. does

Sentynl Therapeutics, Inc. is a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited (India), founded in 2015 and headquartered in Solana Beach, California. The company specializes in acquiring, developing, and commercializing treatments for rare and ultra-rare pediatric genetic diseases through a buy-and-commercialize model, with a current commercial portfolio of three FDA-approved therapies: ZYCUBO (copper histidinate) for Menkes disease, Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome, and NULIBRY (fosdenopterin) for molybdenum cofactor deficiency Type A. Its technology foundation rests on proprietary drug formulations including subcutaneous copper replacement, farnesyltransferase inhibition, and cPMP substrate therapy, each targeting fatal genetic conditions that previously had no approved treatment options.

The business model centers on pharmaceutical product sales through specialty pharmacy distribution channels in the United States, supplemented by outbound royalty obligations on licensed products (e.g., tiered royalties to Cyprium Therapeutics on ZYCUBO net sales plus up to $128-129 million in aggregate sales milestones). Sentynl monetizes its portfolio through a sales-led enterprise field model employing Rare Disease Key Account Managers, Medical Science Liaisons, and an inside Key Account Consultant team that engages healthcare professionals at treatment centers of excellence. The Sentynl Cares patient support program facilitates insurance navigation and affordability assistance, while a Managed Access Program (now operated by Amsterdam-based myTomorrows) extends reach for international patients. Revenue figures are not publicly disclosed, though analyst projections estimate ZYCUBO peak sales of approximately $50 million and company-wide profitability by FY28. With 11-50 employees, the firm operates a focused ultra-rare disease specialty model targeting indications with no approved competitors.

Sentynl Therapeutics, Inc. firmographics

Firmographics
Name
Sentynl Therapeutics, Inc.
Legal name
Sentynl Therapeutics, Inc.
Website
https://sentynl.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Sentynl Therapeutics is a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences that acquires, develops, and commercializes FDA-approved therapies for rare and ultra-rare pediatric genetic diseases including Menkes, Progeria, and MoCD Type A.
Ownership category
akta.pro rank

Sentynl Therapeutics, Inc. industry classification

Industry
Product category
Rare Disease Therapeutics
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Rare disease therapeutics
  • Orphan drug development
  • Specialty pharmaceuticals
  • Pediatric genetic diseases
  • Ultra-rare disease treatments

Where Sentynl Therapeutics, Inc. is headquartered

Location

Headquarters

HQ city
Solana Beach
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Sentynl Therapeutics, Inc. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Revenue from sales of FDA-approved rare disease therapies including ZYCUBO for Menkes disease, Zokinvy for Progeria, and NULIBRY for MoCD Type A. Products distributed through specialty pharmacy channels with patient support programs.
  2. Royalty Revenue: Sentynl pays royalties to Cyprium Therapeutics on ZYCUBO net sales (tiered royalties) plus up to $128-129 million in aggregate sales milestones, per 2023 agreement. Also likely pays royalties on other licensed products.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goPatient assistance program for US residents

Go-to-market motion4 records

Distribution channels3 records

Marketing channels6 records

Sentynl Therapeutics, Inc. product offering

Product offering

Core offering

Sentynl Therapeutics is a U.S.-based commercial-stage biopharmaceutical company that develops, in-licenses, and commercializes FDA-approved drug therapies for ultra-rare pediatric genetic diseases. Its marketed portfolio comprises ZYCUBO (copper histidinate) for Menkes disease, Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome, and NULIBRY (fosdenopterin) for molybdenum cofactor deficiency Type A, distributed through specialty pharmacy channels and supported by the Sentynl Cares patient access program.

Product overview

Sentynl Therapeutics is a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences, focused on acquiring, developing, and commercializing treatments for rare and ultra-rare diseases. The company's commercial portfolio includes three FDA-approved products: ZYCUBO (copper histidinate) for Menkes disease, Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome, and NULIBRY (fosdenopterin) for molybdenum cofactor deficiency Type A. Additionally, Sentynl is advancing Progerinin through Phase 2A trials for Progeria. The company operates exclusively in the United States and supports patients through the Sentynl Cares patient access program.

Differentiator

Problem solved

Functional benefit

Brands

  • Sentynl Cares: Patient access and support program offering assistance with insurance coverage, affordability issues, and treatment education for patients prescribed Sentynl therapies.

Products and services

  • ZYCUBO (copper histidinate) FDA-approved copper replacement therapy for the treatment of Menkes disease in pediatric patients. Administered subcutaneously as a lyophilized powder reconstituted for injection, it is the first and only approved treatment for this rare, fatal genetic disorder affecting copper absorption and transport, demonstrating 78–80% reduction in mortality risk in early-treated patients.
  • Zokinvy (lonafarnib) FDA-approved oral farnesyltransferase inhibitor treatment for Hutchinson-Gilford Progeria Syndrome and processing-deficient progeroid laminopathies. It is the only FDA-approved treatment for progeria, a fatal genetic disorder causing premature aging in children, with approvals in the US (2020), EU (2022), Great Britain (2022), and Japan (2024).
  • NULIBRY (fosdenopterin) Approved substrate replacement therapy for molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that progresses rapidly in infants with a median overall survival age of about four years. Approved in the US (2021), EU (2022), Israel (2022), and Great Britain (2024).
  • Progerinin (SLC-D011) Investigational drug candidate for Hutchinson-Gilford Progeria Syndrome currently in Phase 2A clinical trials. Licensed from PRG S&T, with Sentynl gaining full rights upon milestone completion, advancing the company's pipeline in rare aging diseases.
  • Sentynl Cares Patient access and support program providing insurance navigation, affordability assistance, treatment follow-up, and educational resources for US residents prescribed Sentynl rare disease therapies, helping patients access approved treatments such as ZYCUBO, Zokinvy, and NULIBRY.

Quantifiable outcome

  • 78-80% reduction in risk of death for early-treated Menkes disease patients (median survival 177.1 months vs 17.6 months untreated)
  • +2 more outcomes

Companies that use Sentynl Therapeutics, Inc.

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Sentynl Therapeutics, Inc. technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Sentynl Therapeutics, Inc. partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • PRG S&TcoreStrategic or Co-development Partner · 16 March 2026Sentynl entered agreement with Korean company PRG S&T to license Progerinin (SLC-D011), an investigational drug for Hutchinson-Gilford Progeria Syndrome currently in Phase 2A trials. Deal allows Sentynl to begin clinical development with full rights potentially acquired upon milestone completion, aiming to develop therapies for rare aging diseases.
  • Cyprium Therapeutics (Fortress Biotech)coreStrategic or Co-development Partner · 23 February 2026Sentynl acquired CUTX-101 (ZYCUBO) development and commercialization rights from Cyprium in December 2023. Cyprium retains tiered royalties on net sales and up to $128-129 million in sales milestones. Sentynl purchased PRV for $205 million in February 2026. Joint Steering Committee oversees continued development.
  • myTomorrowscoreStrategic or Co-development Partner · 10 December 2025Sentynl transitioned its Managed Access Program (MAP) to myTomorrows, a global healthtech company based in Amsterdam. The partnership aims to expand the program's reach and improve access to treatments for ultra-rare conditions like Hutchinson-Gilford Progeria Syndrome, with potential extension to other access programs.
  • Eiger BioPharmaceuticalscoreOEM/ Whitelabel/ Licensing Partner · 3 May 2024Sentynl acquired global proprietary rights to Zokinvy (lonafarnib) from Eiger BioPharmaceuticals in May 2024 following court-approved sale amid Eiger's bankruptcy proceedings. Zokinvy is approved in US (2020), EU, Great Britain (2022), and Japan (2024) for progeria treatment.
  • Rady Children's Institute for Genomic MedicineminorStrategic or Co-development Partner · 20 July 2023Sentynl is a founding member of BeginNGS program supporting newborn screening for 419 treatable genetic disorders. Phase 2 support to identify treatable genetic diseases in newborns through genomic sequencing.
  • BridgeBio PharmacoreOEM/ Whitelabel/ Licensing Partner · 8 March 2022Asset purchase agreement for NULIBRY (fosdenopterin) for treatment of MoCD Type A. NULIBRY is first and only approved therapy in US, EU, Israel, and Great Britain for this ultra-rare, life-threatening genetic disorder.
  • Menkes FoundationminorStrategic or Co-development PartnerSentynl joins the global Menkes disease community including the Menkes Foundation in recognizing Menkes Disease Awareness Month. Collaboration on disease awareness and patient support.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Sentynl Therapeutics, Inc. competitors and assessment

Company assessment

Broad incumbents

  • Recordati Rare Diseases: Pharmaceutical group with dedicated rare disease division offering treatments for rare conditions globally. Comparable in rare disease commercialization but operates within broader specialty pharma portfolio.
  • Alexion Pharmaceuticals (AstraZeneca Rare Disease): Pioneer in rare disease biopharmaceuticals, now part of AstraZeneca. Comparable ultra-rare disease focus with established global infrastructure but operates at significantly larger scale as part of a major pharma.

Emerging players

  • Alnylam Pharmaceuticals: Commercial-stage biopharmaceutical company developing RNA interference therapeutics for rare genetic diseases. Comparable focus on rare diseases with novel therapeutic modalities and similar ultra-rare disease commercial dynamics.
  • Ionis Pharmaceuticals: Biopharmaceutical company developing antisense oligonucleotide therapies for serious and rare diseases. Comparable in targeting rare genetic conditions with novel therapeutic platforms and similar patient population scale.

Direct peers

  • Amicus Therapeutics: Biopharmaceutical company developing treatments for rare metabolic diseases including lysosomal storage disorders. Comparable focus on genetic rare diseases with high unmet need and similar commercial scale.
  • BridgeBio Pharma: Genetic disease-focused biopharmaceutical company that developed NULIBRY before selling it to Sentynl. Direct comparable in ultra-rare genetic disease therapeutic development and commercialization strategy.
  • Sarepta Therapeutics: Focused on rare neuromuscular diseases with multiple approved genetic medicines. Comparable strategy of acquiring/developing orphan drugs for small patient populations with high pricing power.
  • Ultragenyx Pharmaceutical: Commercial-stage biopharmaceutical company focused exclusively on rare and ultra-rare genetic diseases with multiple FDA-approved products. Highly comparable business model of developing and commercializing therapies for small patient populations with high unmet need.
  • BioMarin Pharmaceutical: Global biopharmaceutical company specializing in rare genetic diseases with multiple approved therapies. Comparable focus on ultra-rare pediatric disorders and similar commercial model targeting specialty physicians and treatment centers.
  • Swedish Orphan Biovitrum (Sobi): Specialty biopharmaceutical company focused on rare diseases with established European and US operations. Comparable orphan drug commercialization model targeting ultra-rare patient populations across multiple geographies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Sentynl Therapeutics, Inc. social profiles

Digital presence

Sentynl Therapeutics, Inc. compliance and trust

Trust signal

Compliance1 record

Sentynl Therapeutics, Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sentynl Therapeutics, Inc. leadership team

Management profile

Number of profiles

Profiles5 records

Sentynl Therapeutics, Inc. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sentynl Therapeutics, Inc. M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sentynl Therapeutics, Inc.

What does Sentynl Therapeutics, Inc. do?

Sentynl Therapeutics is a U.S.-based commercial-stage biopharmaceutical company that develops, in-licenses, and commercializes FDA-approved drug therapies for ultra-rare pediatric genetic diseases. Its marketed portfolio comprises ZYCUBO (copper histidinate) for Menkes disease, Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome, and NULIBRY (fosdenopterin) for molybdenum cofactor deficiency Type A, distributed through specialty pharmacy channels and supported by the Sentynl Cares patient access program.

Is Sentynl Therapeutics, Inc. a public or private company?

Sentynl Therapeutics, Inc. is a private company. It is classified as corporate owned and is currently operating.

When was Sentynl Therapeutics, Inc. founded?

Sentynl Therapeutics, Inc. was founded in 2015. It employs 11 to 50 people.

Where is Sentynl Therapeutics, Inc. based?

Sentynl Therapeutics, Inc. is headquartered in Solana Beach, United States, in the North America region.

How does Sentynl Therapeutics, Inc. make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are royalty Revenue.

Who are Sentynl Therapeutics, Inc.'s main competitors?

Broad incumbents on record are Recordati Rare Diseases and Alexion Pharmaceuticals (AstraZeneca Rare Disease). Emerging players are Alnylam Pharmaceuticals and Ionis Pharmaceuticals. Direct peers are Amicus Therapeutics, BridgeBio Pharma, Sarepta Therapeutics, Ultragenyx Pharmaceutical, BioMarin Pharmaceutical and Swedish Orphan Biovitrum (Sobi).

Does Sentynl Therapeutics, Inc. have an API?

No public API is recorded for Sentynl Therapeutics, Inc..

What industry is Sentynl Therapeutics, Inc. in?

Sentynl Therapeutics, Inc.'s product category is Rare Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics. Its NAICS code is 54171 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
San Diego Business JournalSentynl Watching Over Rare Disease PatientsSentynl Therapeutics, a rare-disease commercialization firm, agreed with Mereo BioPharma to acquire U.S. rights to alvelestat for alpha-1 antitrypsin deficiency-associated lung disease. The deal includes up to $40 million in fees and a Phase 3 trial planned for early 2027. Sentynl also commercializes three FDA-approved drugs and supports access in over 40 countries.pharmaphorumSentynl gets first FDA approval for rare disease MenkesThe FDA has granted first-time approval to Sentynl Therapeutics for Zycubo, a copper replacement therapy treating Menkes disease, resolving previous manufacturing concerns. Clinical trials demonstrated that early treatment significantly improved survival rates, reducing the risk of death by 79% compared to historical controls. This marks a critical development for patients with this rare, fatal disorder as no other FDA-approved treatments previously existed.PharmTechAlvelestat Deal Signals Early Manufacturing Push for AATD-LDSentynl Therapeutics and Mereo BioPharma Group have entered into an option and license agreement for alvelestat, an oral neutrophil elastase inhibitor developed for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Under the deal, Sentynl holds exclusive commercialization options in the United States and global manufacturing rights, while Mereo retains international commercial rights and leads global development. The companies are initiating early manufacturing coordination during the option period to support a potential phase 3 study that could begin as early as 2027.PharmTechPharmTech Weekly Roundup—August 14, 2026Bristol Myers Squibb announced a $2.3 billion modular manufacturing campus in Houston designed to handle small molecules, biologics, and antibody-drug conjugates. Sentynl and Mereo entered an option deal for the oral elastase inhibitor alvelestat, prioritizing early CMC and scale-up planning ahead of Phase 3 trials. The pharmaceutical industry is also focusing on sustainability compliance through the new CPHI Sustainability Summit and addressing AI implementation risks in manufacturing.BioSpaceSentynl bets up to $475M in licensing deal for Mereo’s rare lung disease assetSentynl Therapeutics has secured an exclusive option to commercialize Mereo BioPharma’s investigational drug alvelestat for alpha-1 antitrypsin deficiency-associated lung disease in the U.S. Under the agreement, Sentynl can pay up to $475 million in total potential milestones and royalties to Mereo upon exercising the option and achieving regulatory approval. This deal enables Mereo to advance alvelestat into Phase 3 development starting in 2027.YahooMereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestatMereo BioPharma and Sentynl Therapeutics have signed a licensing agreement granting Sentynl the option to acquire exclusive US commercial rights for alvelestat, a potential treatment for Alpha-1 antitrypsin deficiency-associated lung disease. Under the deal, Mereo retains international rights while Sentynl funds Phase III development and may pay up to $475 million in milestones and royalties if the option is exercised. The partnership aims to advance the therapy toward a global Phase III study potentially starting in early 2027.Pharmaceutical TechnologyMereo BioPharma, Sentynl Therapeutics sign licensing deal for alvelestatMereo BioPharma and Zydus Lifesciences subsidiary Sentynl Therapeutics have signed an option and license agreement granting Sentynl exclusive US commercial rights to alvelestat, a treatment for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). The deal could yield Mereo BioPharma up to $40 million in upfront payments, $435 million in milestone payments, and double-digit royalties on US sales if the option is exercised. This collaboration aims to advance the drug's development towards a Phase III study, which may start in early 2027.Tech TimesOral Pill for Rare Lung Disease Blocks 90% of Damaging Enzyme in Phase 2, Lands $475M DealMereo BioPharma and Sentynl Therapeutics announced an option and licensing agreement for alvelestat, an oral drug for alpha-1 antitrypsin deficiency lung disease, with potential value up to $475 million. Phase 2 trials showed over 90% suppression of neutrophil elastase at 240 mg twice daily. The deal funds a global Phase 3 study, potentially initiating in 2027.ScanXZydus subsidiary Sentynl signs option and license deal for alvelestatSentynl Therapeutics, a subsidiary of Zydus Lifesciences, has entered into an option and license agreement with Mereo BioPharma for alvelestat, which targets Alpha-1 Antitrypsin Deficiency-Associated Lung Disease. The deal grants Sentynl exclusive U.S. commercialization rights and global manufacturing rights, while Mereo retains development responsibilities and rest-of-world rights, potentially earning up to $40 million in payments until NDA filing plus royalties. This agreement highlights Sentynl's strategic expansion into the treatment landscape for a significant lung disease.Investing.comMereo BioPharma licenses alvelestat to Sentynl Therapeutics By Investing.comMereo BioPharma entered into an agreement with Sentynl Therapeutics, a subsidiary of Zydus Lifesciences Limited, to license alvelestat, an investigational drug for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease. Sentynl has the option to acquire U.S. and global manufacturing rights, with potential milestone payments up to $435 million and royalties, while Mereo will lead the Phase 3 trial. The deal includes funding for the study, which could start early in 2027 if the option is exercised.